i
Important informations
Instagram
Portail
Faire un don

Laboratoire

Le laboratoire de recherche en oncologie gynécologique

Le laboratoire de recherche en oncologie gynécologique (LROG) est situé à l’Institut Lady Davis de recherches médicales de l’Hôpital général juif à Montréal, au Québec.

Notre mission est d’améliorer la vie des personnes touchées par les cancers gynécologiques. L’objectif du LROG est de déterminer les lacunes importantes dans les connaissances et d’utiliser la science fondamentale et les connaissances cliniques pour répondre aux aspects non étudiés. Nos objectifs comprennent la compréhension des mécanismes de développement des cancers gynécologiques, l’identification de leurs vulnérabilités et de leur réponse /résistance au traitement ainsi que la découverte de nouvelles thérapies moléculaires ciblées, efficaces et moins toxiques.

Les types de recherche effectués touchent aux thèmes principaux suivants :

  • Cibler les voies de réparation de l’ADN dans les cancers gynécologiques

  • Modulation épigénétique et impact sur le microenvironnement tumoral

  • Élaboration et validation de biomarqueurs prédictifs/pronostiques

  • Développement d’une plateforme de modèle préclinique pour la prédiction précise de l’efficacité thérapeutique des thérapies ciblées dans les essais cliniques.

La biobanque du cancer gynécologique de l’Hôpital général juif est le résultat de 20 ans de collaborations entre les patients, les cliniciens, les scientifiques et notre laboratoire. Nous avons une large biobanque (tissu, sang, ascite) d’échantillons de patients tout au long de leurs traitements.

Notre biobanque d’oncologie gynécologique est une riche source d’échantillons biologiques qui ont aidé notre équipe de recherche à faire des découvertes importantes dans le domaine des cancers gynécologiques. Cela est rendu possible grâce aux dons généreux des patients et de leurs familles ainsi qu’aux organismes de financement suivants :

  • Fonds de Recherche du Québec – Santé
  • Instituts de recherche en santé du Canada (IRSC)
  • Fonds israélien de recherche sur le cancer
  • Fondation Gloria Girls Gloria Shapiro
  • Fonds Susan et Jonathan Wener
  • Fondation canadienne pour la santé des femmes
  • Fonds commémoratif Francine Grzywacz
  • Fondation Friends for Life
  • Fonds Garber
  • Association israélienne contre le cancer
  • Fondation de l’HGJ
  • Fonds de la famille Levy
  • Réseau de recherche sur le cancer
  • Fonds commémoratif Georgette Duchaine
  • Fonds Visman de l’Université de Tel Aviv
  • Week-end pour vaincre les cancers féminins

Meet the Team

Walter Gotlieb 1

Recherche

Les types de recherches menées portent sur les thèmes suivants :

  • Cibler les voies de réparation de l’ADN dans les cancers gynécologiques: l’altération de l’expression des gènes de réparation est une caractéristique commune à de nombreux cancers gynécologiques. Les altérations de la réparation de l’ADN peuvent conduire à l’initiation de la tumeur et peuvent être dues à des mutations génétiques, à la régulation transcriptionnelle et aux modifications épigénétiques. Ces altérations peuvent également présenter des vulnérabilités à ces cellules cancéreuses qui peuvent être exploitées. Grâce au soutien de nos patientes-partenaires, notre équipe étudie des échantillons biologiques de patientes afin de déterminer les changements dans les protéines de réparation de l’ADN dans le développement du cancer de l’ovaire et de l’endomètre.

  • Modulation épigénétique et son impact sur le microenvironnement tumoral : le microenvironnement tumoral (TME) est devenu un domaine de recherche important. Nous comprenons maintenant qu’il existe des facteurs immunosuppresseurs qui favorisent la tumorigénèse et les interactions entre les cellules tumorales et immunitaires et les changements phénotypiques immunitaires qui influencent la réponse / résistance au traitement.

  • Développement et validation de biomarqueurs prédictifs/pronostiques : une partie de notre mission consiste à personnaliser le traitement des patients et à fournir le bon traitement, au bon moment, au bon patient. L’identification de biomarqueurs pour prédire la réponse à un traitement donné peut potentiellement éviter le sous-traitement ou le surtraitement des patients. L’utilisation des marqueurs pour les déficiences des voies de réparation de l’ADN et les tests non invasifs, tels que l’ADN tumoral circulant, constituent des nouveaux domaines d’intérêt dans notre laboratoire.

  • Développement d’une plateforme de modèles précliniques : ce thème aborde deux domaines importants : 1) comprendre la biologie fondamentale et l’étiologie de l’initiation et de la progression du cancer gynécologique, et 2) établir des modèles précliniques cliniquement pertinents pour a) améliorer la médecine de précision et b) développer une plateforme pour la prédiction précise de l’efficacité thérapeutique des thérapies ciblées dans les essais cliniques.

Les projets en cours comprennent :

  • Étudier les cancers gynécologiques rares grâce au séquençage à haut débit des tumeurs soutenu par l’initiative Terry Fox – Marathon de l’espoir et l’élaboration d’un registre national des cancers rares par l’entremise de la Société de gynéco-oncologie du Canada et de cancer de l’ovaire Canada

  • Étudier le rôle de l’interleukine-10 dans le cancer de l’ovaire

  • Développement d’un nouveau biomarqueur de protéine de réparation de l’ADN (PARG) dans le cancer de l’ovaire pour déterminer la réponse au traitement.

  • Étudier rôle des inhibiteurs de PARP et du HRD dans les cancers de l’endomètre

  • Identification de nouveaux sous-groupes moléculaires de carcinome séreux de l’ovaire de haut grade traités par chimiothérapie néoadjuvante : impact sur le pronostic et le traitement.

  • Étudier l’importance de la chirurgie robotique pour les patientes atteintes de cancers gynécologiques.

Lorem ipsum dolor sit amet consectetur adipisicing elit. Maxime mollitia, molestiae quas vel sint commodi repudiandae consequuntur voluptatum laborum numquam blanditiis harum quisquam eius sed odit fugiat iusto fuga praesentium optio, eaque rerum! Provident similique accusantium nemo autem. Veritatis obcaecati tenetur iure eius earum ut molestias architecto voluptate aliquam nihil, eveniet aliquid culpa officia aut! Impedit sit sunt quaerat, odit, tenetur error, harum nesciunt ipsum debitis quas aliquid. Reprehenderit, quia. Quo neque error repudiandae fuga? Ipsa laudantium molestias eos sapiente officiis modi at sunt excepturi expedita sint? Sed quibusdam recusandae alias error harum maxime adipisci amet laborum. Perspiciatis minima nesciunt dolorem! Officiis iure rerum voluptates a cumque velit quibusdam sed amet tempora. Sit laborum ab, eius fugit doloribus tenetur fugiat, temporibus enim commodi iusto libero magni deleniti quod quam consequuntur! 

L'équipe

Dr. Walter Gotlieb

Walter Gotlieb, MD, PhD

Chercheur principal

After graduating with a BSc in Biology from Nebraska Wesleyan University, Koren Mann obtained a PhD in Pathology/Immunology from Boston University School of Medicine. Following that, she completed a Postdoctoral Fellowship in Oncology at McGill, where she investigated the use of arsenic as a potential chemotherapy in cancer treatment. Today, she is the Chair of the Department of Pharmacology and Therapeutics, an Associate Member of the Department of Medicine, and a Senior Investigator at the Lady Davis Institute for Medical Research.

Dr. Melica N. Brodeur

Melica Brodeur, MD, MSc

Chercheuse principale

After graduating with a BSc in Biology from Nebraska Wesleyan University, Koren Mann obtained a PhD in Pathology/Immunology from Boston University School of Medicine. Following that, she completed a Postdoctoral Fellowship in Oncology at McGill, where she investigated the use of arsenic as a potential chemotherapy in cancer treatment. Today, she is the Chair of the Department of Pharmacology and Therapeutics, an Associate Member of the Department of Medicine, and a Senior Investigator at the Lady Davis Institute for Medical Research.

Walter Gotlieb 2

Suzie Lau, MD, MSc

Cochercheuse

After graduating with a BSc in Biology from Nebraska Wesleyan University, Koren Mann obtained a PhD in Pathology/Immunology from Boston University School of Medicine. Following that, she completed a Postdoctoral Fellowship in Oncology at McGill, where she investigated the use of arsenic as a potential chemotherapy in cancer treatment. Today, she is the Chair of the Department of Pharmacology and Therapeutics, an Associate Member of the Department of Medicine, and a Senior Investigator at the Lady Davis Institute for Medical Research.

Walter Gotlieb 2

Shannon Salvador, MD, MSc

Cochercheuse

After graduating with a BSc in Biology from Nebraska Wesleyan University, Koren Mann obtained a PhD in Pathology/Immunology from Boston University School of Medicine. Following that, she completed a Postdoctoral Fellowship in Oncology at McGill, where she investigated the use of arsenic as a potential chemotherapy in cancer treatment. Today, she is the Chair of the Department of Pharmacology and Therapeutics, an Associate Member of the Department of Medicine, and a Senior Investigator at the Lady Davis Institute for Medical Research.

Associé(e) de recherche

Walter Gotlieb 2

Amber Yasmeen, PhD

Team Arsenic

Cynthia is the Mann lab manager. She offers support to the students with their projects, experiments and troubleshooting. She maintains a productive and positive lab environment. One of her projects involves the creation of arsenic 3 methyltransferase (As3MT) flox mice. These mice are an important tool in dissecting the role of tissue-specific As3MT in arsenic toxicity, as well as potentially identifying alternative As3MT functions.
Walter Gotlieb 2

Maroua Mbarik, PhD

Team Copper

Mitra is a research associate in the Mann Lab. After finishing her BSc in Physiology at McGill, she began her career at the Lady Davis Institute. Her project explores the role of copper, a metal commonly found in drinking water, in the progression of amyotrophic lateral sclerosis.

Assistante de recherche clinique

Walter Gotlieb 2

Angela Tatar, MSc

Team OPE

Braeden is a PhD candidate in the Department of Pharmacology. He completed an Honours Bachelor of Science at Queen’s University with a specialization in Drug Development and Human Toxicology. His project focuses on elucidating the consequences of organophosphate esters exposure on macrophage function.

Boursiers cliniques

Walter Gotlieb 2

Gabriel Levin, MD

Team Arsenic

Nivetha is a PhD candidate in the Department of Experimental Medicine. She completed her BSc in Biochemistry at Concordia University. Her project focuses on how a co-exposure to metals, such as arsenic and cadmium, affects the progression of atherosclerosis.

Walter Gotlieb 2

David Knigin, MD, PhD

Team Lymphoma

Madelyn is a PhD student in the department of Experimental Medicine. She uses mouse modelling to study Diffuse Large B Cell Lymphoma. In particular, she has found that mutations in the transcription factor STAT6 are enriched at disease relapse, and I study how this contributes to remodeling of the tumour microenvironment.

Walter Gotlieb 2

Rowa Bakadlag

Team Tungsten

Rowa is a PhD candidate in the department of Experimental Medicine. She completed her BSc in Microbiology and Immunology in Saudi Arabia, then completed two MScs in Genetics and Parasitology at McGill University. Her work investigates tungsten toxicity focusing on SLC2A2 as a transporter and the effects on mature B lymphocytes.

Étudiant(e) à la maîtrise

Walter Gotlieb 2

Yoav Brezinov, MD

Team Vaping

Vincenza is an MSc. Student in the Department of Pharmacology. She completed her BSc. in Pharmacology at McGill University. Her project aims to elucidate the role of e-cigarette use on the murine cardiopulmonary system. Specifically, she is focusing on metal deposition in the lungs, and the progression of atherosclerosis due to these exposures.

Walter Gotlieb 2

Paul-Adrien Guigue

Team Arsenic

Nazli Zengin is an MSc. student in the Department of Pharmacology. She has a background in pharmacology and environment. Her work currently focuses on elucidating how sex and diet modulate arsenic toxicity and its immunological and cardiovascular consequences.

Walter Gotlieb 2

Andrew Little

Team Arsenic

Andrew is an MSc. student in the Department of Pharmacology who graduated from the B.Sc. program in Biochemistry at McGill in 2021. He works on a proteomics project centred around Arsenic 3-Methyltransferase and the question about whether it serves an additional function.

Walter Gotlieb 2

Raymond Tu

Team Tungsten

Raymond is an MSc. Student in the Department of Pharmacology who completed his BSc. in Environmental Health Sciences from the UNC Chapel Hill as a as a Morehead-Cain Scholar. He received the McCall MacBain Scholarship in 2021. His project studies the mechanism of tungsten on mTORC1, a major regulator of cell growth and proliferation.

Walter Gotlieb 2

Nikola Kukolj

Team Arsenic

Nikola is an incoming MSc Student who completed his undergraduate degree in
Microbiology and Immunology at McGill University. He is currently working on an NSERC
summer project that assesses the functional characterization of macrophages exposed to arsenic using murine bone marrow-derived macrophages.

Undergraduate Students

Walter Gotlieb 2

Roni Juran

Team Vaping

Roni is a second-year BSc student in Chemistry at McGill. As an undergraduate student, she works on various projects across the lab, but is currently focused elucidating the correlation between nonalcoholic fatty liver disease and vaping.

Publications

  • Abitbol J, Kucukyazici B, Brin S, Lau S, Salvador S, Ramanakumar AV, et al. Impact of robotic surgery on patient flow and resource use intensity in ovarian cancer. J Robot Surg. 4 août 2022;
  • Gomolin A, Gotlieb W, Lau S, Salvador S, Racovitan F, Abitbol J. Mandate to evaluate robotic surgery implementation: a 12-year retrospective analysis of impact and future implications. J Robot Surg. août 2022;16(4):783‑8.
  • Matanes E, Eisenberg N, Mitric C, Yasmeen A, Ismail S, Raban O, et al. Surgical and oncological outcomes of sentinel lymph node sampling in elderly patients with intermediate to high-risk endometrial carcinoma. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 4 juill 2022;32(7):875‑81.
  • Matanes E, Cantor T, AlShehri E, Salvador S, Lau S, Gotlieb W. Surgical technique for sentinel lymph node sampling in endometrial cancer using the articulated HOOK monopolar instrument. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 4 juill 2022;32(7):951‑2.
  • Matanes E, Amajoud Z, Salvador S, Lau S, Gotlieb W. Four protective maneuvers in minimal invasive surgery of endometrial cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 4 juill 2022;32(7):953‑4.
  • Matanes E, López-Ozuna VM, Octeau D, Baloch T, Racovitan F, Dhillon AK, et al. Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents. Front Oncol. 2021;11:745981.
  • Kessous R, Wissing MD, Laskov I, Abitbol J, Bitharas J, Agnihotram VR, et al. Multiple lines of chemotherapy for patients with high-grade ovarian cancer: Predictors for response and effect on survival. Int J Cancer. 1 mai 2021;148(9):2304‑12.
  • Kessous R, Matanes E, Laskov I, Wainstock T, Abitbol J, Yasmeen A, et al. Carboplatin plus paclitaxel weekly dose-dense chemotherapy for high-grade ovarian cancer: A re-evaluation. Acta Obstet Gynecol Scand. mars 2021;100(3):453‑8.
  • López-Ozuna VM, Kogan L, Hachim MY, Matanes E, Hachim IY, Mitric C, et al. Identification of Predictive Biomarkers for Lymph Node Involvement in Obese Women With Endometrial Cancer. Front Oncol. 2021;11:695404.
  • Kessous R, Wissing MD, Piedimonte S, Abitbol J, Kogan L, Laskov I, et al. CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer. Acta Obstet Gynecol Scand. juill 2020;99(7):933‑40.
  • Piedimonte S, Kessous R, Laskov I, Abitbol J, Kogan L, Yasmeen A, et al. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer. J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC. nov 2020;42(11):1339‑45.
  • Kogan L, Matanes E, Wissing M, Mitric C, How J, Amajoud Z, et al. The added value of sentinel node mapping in endometrial cancer. Gynecol Oncol. juill 2020;158(1):84‑91.
  • Baloch T, López-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, et al. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1. BMC Cancer. 10 janv 2019;19(1):44.
  • Octeau D, Kessous R, Klein K, Kogan L, Pelmus M, Ferenczy A, et al. Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. Mol Cancer Res MCR. déc 2019;17(12):2422‑31.
  • Kessous R, Octeau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, et al. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Gynecol Oncol. mars 2018;148(3):553‑8.
  • Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, et al. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. mars 2017;144(3):474‑9.
  • Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 8 sept 2017;17(1):638.
  • Laskov I, Abou-Nader P, Amin O, Philip CA, Beauchamp MC, Yasmeen A, et al. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. sept 2016;26(7):1213‑21.
  • Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, et al. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol. sept 2014;134(3):607‑14.
  • He G, Holcroft CA, Beauchamp MC, Yasmeen A, Ferenczy A, Kendall-Dupont J, et al. Combination of serum biomarkers to differentiate malignant from benign ovarian tumours. J Obstet Gynaecol Can JOGC J Obstet Gynecol Can JOGC. juin 2012;34(6):567‑74.
  • Beauchamp MC, Yasmeen A, Knafo A, Gotlieb WH. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol. 2010;2010:257058.
  • Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, et al. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol Oncol. nov 2009;115(2):193‑8.

Collaborations

Dr. Wilson Miller, Lady Davis Institute, Montreal

Dr. Sonia del Rincon, Lady Davis Institute, Montreal

Dr. Carolyn Baglole, RI-MUHC, McGill University, Montreal

Dr. Jun Ding, RI-MUHC, McGill University, Montreal

Dr. Susan Gaskin, Department of Chemical Engineering, McGill University, Montreal

Dr. Bernard Robaire, Department of Pharmacology McGill University, Montreal

Dr. Brandon Pearson, Columbia University, New York

Dr. John Wise, University of Louisville, Kentucky

News/Milestones

Dr. Wilson Miller, Lady Davis Institute, Montreal

Dr. Sonia del Rincon, Lady Davis Institute, Montreal

Dr. Carolyn Baglole, RI-MUHC, McGill University, Montreal

Dr. Jun Ding, RI-MUHC, McGill University, Montreal

Dr. Susan Gaskin, Dep’t of Chemical Engineering, McGill University, Montreal

Dr. Bernard Robaire, Dep’t of Pharmacology McGill University, Montreal

Dr. Brandon Pearson, Columbia University, New York

Dr. John Wise, University of Louisville, Kentucky

Lorem ipsum dolor sit amet consectetur adipisicing elit. Maxime mollitia, molestiae quas vel sint commodi repudiandae consequuntur voluptatum laborum numquam blanditiis harum quisquam eius sed odit fugiat iusto fuga praesentium optio, eaque rerum! Provident similique accusantium nemo autem. Veritatis obcaecati tenetur iure eius earum ut molestias architecto voluptate aliquam nihil, eveniet aliquid culpa officia aut! Impedit sit sunt quaerat, odit, tenetur error, harum nesciunt ipsum debitis quas aliquid. Reprehenderit, quia. Quo neque error repudiandae fuga? Ipsa laudantium molestias eos sapiente officiis modi at sunt excepturi expedita sint? Sed quibusdam recusandae alias error harum maxime adipisci amet laborum. Perspiciatis minima nesciunt dolorem! Officiis iure rerum voluptates a cumque velit quibusdam sed amet tempora. Sit laborum ab, eius fugit doloribus tenetur fugiat, temporibus enim commodi iusto libero magni deleniti quod quam consequuntur! 

  1. How iMALDI can improve clinical diagnostics. Popp, R., Basik, M., Spatz, A., Batist, G., Zahedi, R.P., Borchers, C.H., 2018. Analyst Clin. Chem. 64, 1271–1272. 143, 2197–2203.
  2. Immuno-MALDI-TOF-MS in the Clinic. Zahedi, R.P., Parker, C.E., Borchers, C.H., 2018.

Prix et récompenses

Walter Gotlieb :

Melica Brodeur :

Braeden Giles:

  • Centre for Research in Reproduction and Development Fellowship, 2023
  • 3 Minute Thesis – Pharmacology McGill, 2023

Andrew Little:

  • Master’s Training Scholarship – CIHR, 2022

Nikola Kukolj:

  • Undergraduate Student Research Awards – NSERC, 2023

Links

Titre

Lorem ipsum dolor sit amet consectetur adipisicing elit. Maxime mollitia, molestiae quas vel sint commodi repudiandae consequuntur voluptatum laborum numquam blanditiis harum quisquam eius sed odit fugiat iusto fuga praesentium optio, eaque rerum! Provident similique accusantium nemo autem. Veritatis obcaecati tenetur iure eius earum ut molestias architecto voluptate aliquam nihil, eveniet aliquid culpa officia aut! Impedit sit sunt quaerat, odit, tenetur error, harum nesciunt ipsum debitis quas aliquid. Reprehenderit, quia.

Titre

Events

Dr. Wilson Miller, Lady Davis Institute, Montreal

Dr. Sonia del Rincon, Lady Davis Institute, Montreal

Dr. Carolyn Baglole, RI-MUHC, McGill University, Montreal

Dr. Jun Ding, RI-MUHC, McGill University, Montreal

Dr. Susan Gaskin, Dep’t of Chemical Engineering, McGill University, Montreal

Dr. Bernard Robaire, Dep’t of Pharmacology McGill University, Montreal

Dr. Brandon Pearson, Columbia University, New York

Dr. John Wise, University of Louisville, Kentucky

Lorem ipsum dolor sit amet consectetur adipisicing elit. Maxime mollitia, molestiae quas vel sint commodi repudiandae consequuntur voluptatum laborum numquam blanditiis harum quisquam eius sed odit fugiat iusto fuga praesentium optio, eaque rerum! Provident similique accusantium nemo autem. Veritatis obcaecati tenetur iure eius earum ut molestias architecto voluptate aliquam nihil, eveniet aliquid culpa officia aut! Impedit sit sunt quaerat, odit, tenetur error, harum nesciunt ipsum debitis quas aliquid. Reprehenderit, quia. Quo neque error repudiandae fuga? Ipsa laudantium molestias eos sapiente officiis modi at sunt excepturi expedita sint? Sed quibusdam recusandae alias error harum maxime adipisci amet laborum. Perspiciatis minima nesciunt dolorem! Officiis iure rerum voluptates a cumque velit quibusdam sed amet tempora. Sit laborum ab, eius fugit doloribus tenetur fugiat, temporibus enim commodi iusto libero magni deleniti quod quam consequuntur! 

  1. How iMALDI can improve clinical diagnostics. Popp, R., Basik, M., Spatz, A., Batist, G., Zahedi, R.P., Borchers, C.H., 2018. Analyst Clin. Chem. 64, 1271–1272. 143, 2197–2203.
  2. Immuno-MALDI-TOF-MS in the Clinic. Zahedi, R.P., Parker, C.E., Borchers, C.H., 2018.

Soutien

Nous sommes reconnaissants du soutien financier que nous recevons des organismes de financement et des donateurs privés. Avec votre soutien, nous serons capables de faire des découvertes cliniques significatives pour améliorer les soins aux patients.

Remerciements particuliers à :

Fonds de Recherche du Québec – Santé

Instituts de recherche en santé du Canada (IRSC)

Fondation Gloria Girls Gloria Shapiro

Fondation canadienne pour la santé des femmes

Fonds commémoratif Francine Grzywacz

Fondation Friends for Life 

Fonds Garber 

Association israélienne contre le cancer

Fonds israélien de recherche sur le cancer

Fondation de l’HGJ

Fonds de la famille Levy

Reseau de recherche sur le cancer

Fonds Susan et Jonathan Wener

Fonds Visman de l’Université de Tel Aviv

Week-end pour vaincre les cancers féminins

Contact

Institut Lady Davis de recherches médicales, Hôpital général juif

3755, Ch. Côte Ste-Catherine 
Montréal, Québec H3T 1E2

Maroua Mbarik, PhD

Courriel :

maroua.mbarik@ladydavis.ca

Reception:

(514) 340-8260

Office:

(514) 340-8222 ext. 22760

Lab:

(514) 340-8222 ext. 24257